Vice President, Scientific Innovation for Cardiovascular, Metabolism, Retinal, and Pulmonary Hypertension, Johnson & Johnson
Liangsu is Vice President of Scientific Innovation for Cardiovascular, Metabolism, Retinal, and Pulmonary Hypertension in the regions of West North America, Asian Pacific, Australia, and New Zealand. In this role, she is responsible for creating and implementing the company’s external innovation partnership strategy and portfolio. She is responsible for searching and evaluation of external opportunities, execution of collaboration and licensing deals, evaluation of venture investment opportunities, and review of JLABS residents for Johnson & Johnson Innovations.
Liangsu brings over 25 years of experience in large pharma and small biotech companies and has advanced numerous drug programs from discovery to clinical development across various modalities. She joined Johnson & Johnson from her previous role as Vice President, Head of Biology for biotech start-up, Morphic Therapeutic, where she was accountable for the company’s scientific strategy and portfolio expansion on new targets and new indications. She spearheaded the building of a robust drug discovery portfolio focused on fibrosis, autoimmunity, and immuno-oncology, in addition to her role in the company’s business development, corporate financing, and an oversized IPO. Prior to her time at Morphic Therapeutic, she spent nearly 13 years at Merck, working across a range of metabolic diseases and complications, cardiovascular, and infectious diseases developing a track record for establishing and leading collaborations with partners in academia and industry. She served as the Executive Director, Head of Diabetes & NASH Discovery Research, accountable for the Diabetes and NASH drug discovery portfolio as well as discovery support of clinical development programs. In her early days of industry career, Liangsu worked in multiple biotech companies in San Diego.
Liangsu received her B.Sc. in Genetics and Genetic Engineering from Fudan University in China, followed by her Ph.D. in Biochemistry and Molecular Biology from the University of Calgary, Canada. She has also been trained in Bioinformatics and Computational Biology.